Press ReleaseView printer-friendly version << Back
vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations
-Workforce reduction of 65%
-Prioritization of lead program TTP399, a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients
TTP399 is a novel, oral, liver-selective glucokinase activator that showed ~40% reduction in hypoglycemic episodes compared to placebo in its Phase 2 study and was granted Breakthrough Therapy Designation by the FDA. In October, the Company announced positive results of its mechanistic study showing no increased risk of ketoacidosis. Additionally, zero hypoglycemic episodes occurred in the TTP399 arm while four occurred on placebo.
Type 1 Diabetes (T1D) is an autoimmune disease with no cure affecting over 1.6 million people today in
Due to its shift in strategic focus, the Company:
- Reduced its workforce by approximately 65%;
- Added several consultants with track records of drug approvals with extensive Regulatory, Clinical, and Biostatistics experience;
- Paused vTv’s development activities on HPP737, a PDE4 inhibitor for treatment of psoriasis, while it evaluates strategic options; and
- Continues to support the development of its partnered programs.
“It is always difficult to restructure but this allows us to focus on TTP399 and our future growth,” said
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the
Source: vTv Therapeutics Inc.